I’m not an experienced investor, but I’ve dabbled here and there, and I’m curious what others think about LLY over the next 3-5 years.
Specifically, their diabetes medication, Mounjaro, is in extremely high demand right now as a weight loss drug because it apparently works somewhat differently from Ozempic and other similarly situated products. It doesn’t have FDA approval for weight loss, but the demand is through the roof.
More than that, there seems to be anecdotal support for the idea of using Mounjaro to help treat addiction in a wide variety of patients.
Obviously, LLY is a reliable company and arguably not very risky at the worst of times, but I’m curious if anyone else has opened a position or is thinking about it based on the performance and potential of Mounjaro.
Leave a Reply